Vista Pharma Q1 loss: revenue nil, going concern doubt flagged

Going ConcernRevenue DeclinePat NegativeNegative Operating CashflowDebt Equity ThresholdResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-8.6%Reaction day

₹6.89

prior close

₹6.35

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-8.7% vs market

Pharmaceuticals peers, median of 167sector-0.3%-8.2% vs sector

On the reaction day the stock moved 8.7 pts less than Nifty Microcap 250 and 8.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+9.9

10m

+9.9

15m

+9.9

30m

+5.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-8.6+0.1-8.7-0.3-8.2

Next day

-8.9+0.5-9.4-0.0-8.8

-4.8-0.1-4.7-0.7-4.1

-8.6+0.4-9.0-0.4-8.2

-6.5+0.7-7.2-0.7-5.9

-4.1+0.9-5.0-0.5-3.5

-14.9+1.1-16.1-0.7-14.2

15d

-9.9+1.6-11.5+1.4-11.2

-15.2-0.7-14.5+0.6-15.8

-11.5-3.2-8.2-4.1-7.3

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vista Pharmaceuticals posted a net loss of Rs. 98.59 lakhs in Q1 FY27 against Rs. 129.04 lakhs loss a year ago. Revenue from operations was nil versus Rs. 151.88 lakhs earlier. The company flagged material uncertainty on going concern due to six straight years of losses, negative working capital, cash losses, and loan accounts classified as NPA. Total expenses stood at Rs. 136.70 lakhs. It is awaiting Rs. 922.49 lakhs from convertible warrant holders by Sept 15, 2026.

Likely market impact

Persistent losses, nil revenue, NPA tag and going concern doubt raise serious survival concerns. Warrant call money due Sept 15 is a key milestone.